Improvement of immunogenic chemotherapy by STAT3 inhibition
Article 2015 en
Authors
HY
Heng Yang
TY
Takahiro Yamazaki
FP
Federico Pietrocola
Abstract
1 min read
The inhibition of STAT3 may exert cell-autonomous cytotoxic and cytostatic effects, yet may also stimulate anticancer immunosurveillance through the neutralization of immunosuppressive circuitries. In addition, STAT3 inhibition in cancer cells may stimulate the type 1 interferon response elicited by anthracyclines. This pathway results in an enhanced chemotherapy-associated anticancer immune response with improved therapeutic efficacy. Hence, combination therapies that include immunogenic cell death (ICD) inducers and STAT3 inhibitors can be envisaged.
Michel Obéid, Antoine Tesnière, Theocharis Panaretakis, Roberta Tufi, Nick Joza, Peter Van Endert, François Ghiringhelli, Lionel Apétoh, Nathalie Chaput, Caroline Flament, Evelyn Ullrich, Stéphane de Botton, Laurence Zitvogel, Guido Guido Kroemer
Discussion(0)
No comments yet. Be the first to comment.